GT Biopharma (GTBP) Institutional Ownership $1.74 -0.18 (-9.11%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for GT Biopharma (NASDAQ:GTBP)CurrentInstitutional OwnershipPercentage8.15%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$4.84MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$326.26K Get GTBP Insider Trade Alerts Want to know when executives and insiders are buying or selling GT Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data GTBP Institutional Buying and Selling by Quarter Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> GT Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/8/2024 DekaBank Deutsche Girozentrale978,358$2.77M0.0%-10.5%69.044% 6/4/2024 DekaBank Deutsche Girozentrale1,093,645$47.45M0.1%N/A77.017% 8/2/2023 Bank of Montreal Can596,240$262K0.0%N/A1.596% 1/23/2023 Baskin Financial Services Inc.151,354$134K0.0%N/A0.466% 11/7/2022 Virtu Financial LLC24,864$44K0.0%N/A0.076% 5/5/2022 Russell Investments Group Ltd.11,007$31K0.0%N/A0.033% Get the Latest News and Ratings for GTBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. 5/2/2022 Allspring Global Investments Holdings LLC25,782$74K0.0%N/A0.078% 4/20/2022 Sigma Planning Corp21,400$62K0.0%N/A0.067% 2/14/2022 Gordian Capital Singapore Pte Ltd35,000$107K0.1%N/A0.114% 2/9/2022 Compagnie Lombard Odier SCmA30,000$92K0.0%+100.0%0.098% 2/4/2022 Crumly & Associates Inc.32,163$85K0.0%N/A0.105% 2/3/2022 Brighton Jones LLC11,288$34K0.0%N/A0.037% 1/31/2022Commonwealth Equity Services LLC11,052$33K0.0%N/A0.036% 11/16/2021 Two Sigma Advisers LP51,100$344K0.0%+243.0%0.242% 11/16/2021 Two Sigma Investments LP162,823$1.10M0.0%N/A0.771% 11/15/2021 Marshall Wace LLP16,577$112K0.0%-35.7%0.078% 11/15/2021 Franklin Resources Inc.28,500$192K0.0%N/A0.135% 11/12/2021 Renaissance Technologies LLC84,700$571K0.0%N/A0.401% 11/12/2021 Geode Capital Management LLC424,279$2.86M0.0%+22.4%2.008% 11/10/2021 Goldman Sachs Group Inc.52,426$353K0.0%N/A0.248% 11/9/2021BlackRock Inc.1,155,228$7.79M0.0%-18.3%5.468% 11/8/2021 State Board of Administration of Florida Retirement System18,224$123K0.0%N/A0.086% 11/8/2021 Russell Investments Group Ltd.9,642$64K0.0%N/A0.046% 11/5/2021 Welch Group LLC10,000$67K0.0%N/A0.047% 11/4/2021 Deutsche Bank AG11,400$77K0.0%-25.7%0.054% 11/2/2021 New York State Common Retirement Fund8,230$55K0.0%-59.7%0.039% 8/25/2021 Marshall Wace LLP25,792$400K0.0%N/A0.122% 8/17/2021 Metropolitan Life Insurance Co NY8,782$136K0.0%N/A0.042% 8/17/2021 MetLife Investment Management LLC11,471$178K0.0%N/A0.054% 8/17/2021 Citadel Advisors LLC510,058$7.91M0.0%N/A2.414% 8/16/2021 California State Teachers Retirement System32,878$510K0.0%N/A0.156% 8/16/2021 Charles Schwab Investment Management Inc.57,993$899K0.0%N/A0.274% 8/16/2021 State Street Corp374,704$5.81M0.0%N/A1.773% 8/16/2021 Nuveen Asset Management LLC82,151$1.27M0.0%N/A0.389% 8/16/2021 Marshall Wace LLP25,792$400K0.0%N/A0.122% 8/13/2021 Northern Trust Corp225,457$3.50M0.0%+555.6%1.067% 8/13/2021 Geode Capital Management LLC346,606$5.37M0.0%+165.8%1.641% 8/13/2021 Vanguard Group Inc.982,269$15.23M0.0%+267.0%4.649% 8/12/2021 Legal & General Group Plc2,524$39K0.0%N/A0.012% 8/12/2021 JPMorgan Chase & Co.9,155$142K0.0%N/A0.043% The #1 Coin for November 2024 (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now…8/12/2021 The Manufacturers Life Insurance Company13,758$213K0.0%N/A0.065% 8/11/2021 Bank of New York Mellon Corp58,711$910K0.0%N/A0.278% 8/11/2021BlackRock Inc.1,413,391$21.91M0.0%N/A6.690% 8/11/2021 Deutsche Bank AG15,349$237K0.0%N/A0.073% 8/10/2021 Citigroup Inc.6,134$95K0.0%N/A0.029% 8/6/2021 Ameritas Investment Partners Inc.1,870$29K0.0%N/A0.009% 8/5/2021 Rhumbline Advisers18,634$289K0.0%N/A0.088% 8/2/2021 New York State Common Retirement Fund20,400$316K0.0%N/A0.097% 8/2/2021 Advisor Group Holdings Inc.2,943$45K0.0%+108.3%0.014% 7/31/2021 Davy Global Fund Management Ltd35,113$544K0.1%+33.4%0.166% 7/15/2021 Compagnie Lombard Odier SCmA15,000$233K0.0%N/A0.071% 7/6/2021 Silverleafe Capital Partners LLC104,000$1.61M0.6%N/A0.492% 5/19/2021 Virtu Financial LLC22,741$156K0.0%N/A0.080% 5/19/2021 Squarepoint Ops LLC16,543$113K0.0%N/A0.058% 5/18/2021 Millennium Management LLC27,895$191K0.0%N/A0.098% 5/17/2021 Royal Bank of Canada24,542$167K0.0%N/A0.086% 5/12/2021 Northern Trust Corp34,387$235K0.0%N/A0.121% 5/12/2021 Geode Capital Management LLC130,388$891K0.0%N/A0.459% 5/12/2021 UBS Group AG3,918$27K0.0%N/A0.014% 5/11/2021 Davy Global Fund Management Ltd26,321$180K0.0%N/A0.093% (Data available from 1/1/2016 forward) GTBP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of GTBP shares? During the previous two years, the following institutional investors and hedge funds held shares of GT Biopharma shares: DekaBank Deutsche Girozentrale ($2.77M), and Bank of Montreal Can ($262K), Baskin Financial Services Inc. ($134K).Learn more on GTBP's institutional investors. What percentage of GT Biopharma stock is owned by institutional investors? 8.15% of GT Biopharma stock is owned by institutional investors. Learn more on GTBP's institutional investor holdings. Which institutional investors have been buying GT Biopharma stock? The following institutional investors have purchased GT Biopharma stock in the last 24 months: DekaBank Deutsche Girozentrale ($1.09M), Bank of Montreal Can ($596.24K), and Baskin Financial Services Inc. ($151.35K). How much institutional buying is happening at GT Biopharma? Institutional investors have bought a total of 1,841,239 shares in the last 24 months. This purchase volume represents approximately $14.45M in transactions. Which GT Biopharma major shareholders have been selling company stock? The following institutional investors have sold GT Biopharma stock in the last 24 months: DekaBank Deutsche Girozentrale ($115.29K). How much institutional selling is happening at GT Biopharma? Institutional investors have sold a total of 115,287 shares in the last 24 months. This volume of shares sold represents approximately $326.26K in transactions. Related Companies MiNK Therapeutics Major Shareholders Lisata Therapeutics Major Shareholders Calidi Biotherapeutics Major Shareholders Athira Pharma Major Shareholders GeoVax Labs Major Shareholders iBio Major Shareholders NanoViricides Major Shareholders IN8bio Major Shareholders Bullfrog AI Major Shareholders Tenax Therapeutics Major Shareholders This page (NASDAQ:GTBP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTBP Stock Alerts